We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) closed at $403.30 in the latest trading session, marking a -1.36% move from the prior day. This change lagged the S&P 500's 0.01% gain on the day. On the other hand, the Dow registered a gain of 0.51%, and the technology-centric Nasdaq decreased by 0.28%.
Prior to today's trading, shares of the drugmaker had gained 3% lagged the Medical sector's gain of 4.67% and the S&P 500's gain of 4.83%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company's earnings per share (EPS) are projected to be $4.56, reflecting a 4.11% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $3.04 billion, up 9.78% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.98 per share and a revenue of $11.98 billion, signifying shifts of +4180.95% and +8.75%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Vertex Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Vertex Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Vertex Pharmaceuticals is at present trading with a Forward P/E ratio of 22.74. This valuation marks a premium compared to its industry average Forward P/E of 19.42.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 74, positioning it in the top 30% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
Vertex Pharmaceuticals (VRTX - Free Report) closed at $403.30 in the latest trading session, marking a -1.36% move from the prior day. This change lagged the S&P 500's 0.01% gain on the day. On the other hand, the Dow registered a gain of 0.51%, and the technology-centric Nasdaq decreased by 0.28%.
Prior to today's trading, shares of the drugmaker had gained 3% lagged the Medical sector's gain of 4.67% and the S&P 500's gain of 4.83%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company's earnings per share (EPS) are projected to be $4.56, reflecting a 4.11% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $3.04 billion, up 9.78% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.98 per share and a revenue of $11.98 billion, signifying shifts of +4180.95% and +8.75%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Vertex Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Vertex Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Vertex Pharmaceuticals is at present trading with a Forward P/E ratio of 22.74. This valuation marks a premium compared to its industry average Forward P/E of 19.42.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 74, positioning it in the top 30% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.